vs
MESA LABORATORIES INC（MLAB）与合众银行（OSBC）财务数据对比。点击上方公司名可切换其他公司
合众银行的季度营收约是MESA LABORATORIES INC的1.4倍（$93.8M vs $65.1M），合众银行净利率更高（27.3% vs 5.6%，领先21.7%），过去两年合众银行的营收复合增速更高（15.1% vs 5.1%）
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
合众银行是一家总部位于美国明尼阿波利斯、在特拉华州注册的美国跨国银行机构。截至2025年，它是美国第五大银行，也是美国中西部规模最大的银行，被金融稳定委员会认定为具有系统重要性的金融机构，主营银行、投资、抵押等金融服务。
MLAB vs OSBC — 直观对比
营收规模更大
OSBC
是对方的1.4倍
$65.1M
净利率更高
OSBC
高出21.7%
5.6%
两年增速更快
OSBC
近两年复合增速
5.1%
损益表 — Q3 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $65.1M | $93.8M |
| 净利润 | $3.6M | $25.6M |
| 毛利率 | 64.2% | — |
| 营业利润率 | 12.2% | — |
| 净利率 | 5.6% | 27.3% |
| 营收同比 | 3.6% | — |
| 净利润同比 | 316.6% | 159.2% |
| 每股收益（稀释后） | $0.65 | $0.48 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MLABOSBC
| Q1 26 | — | $93.8M | ||
| Q4 25 | $65.1M | $95.2M | ||
| Q3 25 | $60.7M | $95.9M | ||
| Q2 25 | $59.5M | $75.1M | ||
| Q1 25 | $62.1M | $73.1M | ||
| Q4 24 | $62.8M | $73.2M | ||
| Q3 24 | $57.8M | $71.2M | ||
| Q2 24 | $58.2M | $70.8M |
净利润MLABOSBC
| Q1 26 | — | $25.6M | ||
| Q4 25 | $3.6M | — | ||
| Q3 25 | $2.5M | $9.9M | ||
| Q2 25 | $4.7M | $21.8M | ||
| Q1 25 | $-7.1M | $19.8M | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $3.4M | $23.0M | ||
| Q2 24 | $3.4M | $21.9M |
毛利率MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | 64.2% | — | ||
| Q3 25 | 61.5% | — | ||
| Q2 25 | 62.0% | — | ||
| Q1 25 | 61.8% | — | ||
| Q4 24 | 63.3% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 64.0% | — |
营业利润率MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | 12.2% | 41.2% | ||
| Q3 25 | 7.8% | 13.6% | ||
| Q2 25 | 5.1% | 38.9% | ||
| Q1 25 | 2.4% | 35.8% | ||
| Q4 24 | 9.2% | 34.7% | ||
| Q3 24 | 6.1% | 41.9% | ||
| Q2 24 | 9.6% | 41.2% |
净利率MLABOSBC
| Q1 26 | — | 27.3% | ||
| Q4 25 | 5.6% | — | ||
| Q3 25 | 4.1% | 10.3% | ||
| Q2 25 | 8.0% | 29.0% | ||
| Q1 25 | -11.4% | 27.1% | ||
| Q4 24 | -2.7% | — | ||
| Q3 24 | 5.9% | 32.3% | ||
| Q2 24 | 5.8% | 30.9% |
每股收益（稀释后）MLABOSBC
| Q1 26 | — | $0.48 | ||
| Q4 25 | $0.65 | $0.53 | ||
| Q3 25 | $0.45 | $0.18 | ||
| Q2 25 | $0.85 | $0.48 | ||
| Q1 25 | $-1.30 | $0.43 | ||
| Q4 24 | $-0.31 | $0.42 | ||
| Q3 24 | $0.63 | $0.50 | ||
| Q2 24 | $0.62 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $29.0M | $115.7M |
| 总债务越低越好 | $68.4M | — |
| 股东权益账面价值 | $186.7M | $893.3M |
| 总资产 | $434.8M | $6.8B |
| 负债/权益比越低杠杆越低 | 0.37× | — |
8季度趋势，按日历期对齐
现金及短期投资MLABOSBC
| Q1 26 | — | $115.7M | ||
| Q4 25 | $29.0M | $124.0M | ||
| Q3 25 | $20.4M | $116.5M | ||
| Q2 25 | $21.3M | $141.8M | ||
| Q1 25 | $27.3M | $256.1M | ||
| Q4 24 | $27.3M | $99.3M | ||
| Q3 24 | $24.3M | $115.8M | ||
| Q2 24 | $28.5M | $120.9M |
总债务MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | $68.4M | — | ||
| Q3 25 | $69.4M | — | ||
| Q2 25 | $70.3M | — | ||
| Q1 25 | $71.3M | — | ||
| Q4 24 | $72.2M | — | ||
| Q3 24 | $73.1M | — | ||
| Q2 24 | $74.1M | — |
股东权益MLABOSBC
| Q1 26 | — | $893.3M | ||
| Q4 25 | $186.7M | $896.8M | ||
| Q3 25 | $178.5M | $866.7M | ||
| Q2 25 | $172.5M | $718.6M | ||
| Q1 25 | $159.8M | $694.5M | ||
| Q4 24 | $155.2M | $671.0M | ||
| Q3 24 | $161.5M | $661.4M | ||
| Q2 24 | $150.7M | $619.3M |
总资产MLABOSBC
| Q1 26 | — | $6.8B | ||
| Q4 25 | $434.8M | $6.9B | ||
| Q3 25 | $430.4M | $7.0B | ||
| Q2 25 | $435.7M | $5.7B | ||
| Q1 25 | $433.3M | $5.7B | ||
| Q4 24 | $433.3M | $5.6B | ||
| Q3 24 | $454.1M | $5.7B | ||
| Q2 24 | $440.4M | $5.7B |
负债/权益比MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | 0.37× | — | ||
| Q3 25 | 0.39× | — | ||
| Q2 25 | 0.41× | — | ||
| Q1 25 | 0.45× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.45× | — | ||
| Q2 24 | 0.49× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $18.8M | — |
| 自由现金流经营现金流 - 资本支出 | $18.0M | — |
| 自由现金流率自由现金流/营收 | 27.7% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.17× | — |
| 过去12个月自由现金流最近4个季度 | $37.9M | — |
8季度趋势，按日历期对齐
经营现金流MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | $18.8M | $122.3M | ||
| Q3 25 | $8.2M | $35.9M | ||
| Q2 25 | $1.9M | $24.2M | ||
| Q1 25 | $12.7M | $17.8M | ||
| Q4 24 | $18.1M | $131.5M | ||
| Q3 24 | $5.3M | $48.5M | ||
| Q2 24 | $10.7M | $11.6M |
自由现金流MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | $18.0M | $117.8M | ||
| Q3 25 | $7.1M | $34.7M | ||
| Q2 25 | $884.0K | $23.5M | ||
| Q1 25 | $11.9M | $16.2M | ||
| Q4 24 | $17.3M | $120.7M | ||
| Q3 24 | $3.5M | $46.2M | ||
| Q2 24 | $9.9M | $8.7M |
自由现金流率MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | 27.7% | 123.7% | ||
| Q3 25 | 11.7% | 36.2% | ||
| Q2 25 | 1.5% | 31.2% | ||
| Q1 25 | 19.2% | 22.2% | ||
| Q4 24 | 27.6% | 165.0% | ||
| Q3 24 | 6.0% | 64.9% | ||
| Q2 24 | 16.9% | 12.3% |
资本支出强度MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | 4.7% | ||
| Q3 25 | 1.8% | 1.3% | ||
| Q2 25 | 1.7% | 1.1% | ||
| Q1 25 | 1.2% | 2.2% | ||
| Q4 24 | 1.3% | 14.7% | ||
| Q3 24 | 3.1% | 3.3% | ||
| Q2 24 | 1.5% | 4.2% |
现金转化率MLABOSBC
| Q1 26 | — | — | ||
| Q4 25 | 5.17× | — | ||
| Q3 25 | 3.32× | 3.64× | ||
| Q2 25 | 0.40× | 1.11× | ||
| Q1 25 | — | 0.90× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.54× | 2.11× | ||
| Q2 24 | 3.17× | 0.53× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
OSBC
| Net Interest Income | $81.1M | 87% |
| Noninterest Income | $12.6M | 13% |
